Therapie des metastasierten kastrationsresistenten Prostatakarzinoms
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapie des metastasierten kastrationsresistenten Prostatakarzinoms
Authors
Keywords
-
Journal
UROLOGE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-09
DOI
10.1007/s00120-020-01187-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane).
- (2020) Neeraj Agarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Matthew Smith et al. LANCET ONCOLOGY
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial
- (2018) Pernelle Lavaud et al. EUROPEAN UROLOGY
- Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
- (2018) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): Results for 2nd-line therapy.
- (2018) Daniel Khalaf et al. JOURNAL OF CLINICAL ONCOLOGY
- Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
- (2017) Finn Edler von Eyben et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA
- (2017) Mario Eisenberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme
- (2014) Axel Heidenreich et al. EUROPEAN JOURNAL OF CANCER
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy
- (2013) Peter F.A. Mulders et al. EUROPEAN UROLOGY
- 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
- (2013) Pirkko-Liisa Kellokumpu-Lehtinen et al. LANCET ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
- (2009) William P Harris et al. Nature clinical practice. Urology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started